All In Biotech

Drug Trial Radar · NCT02305888

Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, Respectively

Safety of LEO 43204 0.018%, 0.037% and 0.1% for Actinic Keratosis Applied Once Daily for Three Consecutive Days on Face/Chest, Scalp and Trunk/Extremities, Respectively

Last checked: Nov 20, 2026Latest source record: Mar 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

189

Actual

Start

Mar 2015

Primary completion

Jul 2015

Study completion Aug 2015

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
First posted
Dec 3, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of the trial is to investigate the Safety of LEO 43204 0.018%, 0.037% and 0.1% for actinic keratosis applied once daily for three consecutive days on face/chest, scalp and trunk/extremities, respectively.

Conditions

  • Actinic Keratosis

Interventions

  • LEO 43204Drug

    Treatment of actinic keratosis

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Experiencing DLTs (Dose Limiting Toxicities) Based on LSRs (Local Skin Reactions)Time frame: 8 days / From baseline (Day 1) to Day 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Long Island Skin Cancer and Dermatologic Surgery

    Smithtown, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.